Characterization of the Antibiotic Compound No. 70 Produced byStreptomycessp. IMV-70

Azliyati Azizan,Genrikh S Katrukha,Nina L Tokareva,Galina B Fedorova,Almagul K Khasenova,Boo H Kwa,Assya S Balgimbaeva,Lyudmila P Trenozhnikova

doi:10.1100/2012/594231

Abstract

We describe the actinomycete strain IMV-70 isolated from the soils of Kazakhstan, which produces potent antibiotics with high levels of antibacterial activity. After the research of its morphological, chemotaxonomic, and cultural characteristics, the strain with potential to be developed further as a novel class of antibiotics with chemotherapeutics potential was identified as Streptomyces sp. IMV-70. In the process of fermentation, the strain Streptomyces spp. IMV-70 produces the antibiotic no. 70, which was isolated from the culture broth by extraction with organic solvents. Antibiotic compound no. 70 was purified and separated into individual components by HPLC, TLC, and column chromatography methods. The main component of the compound is the antibiotic 70-A, which was found to be identical to the peptolide etamycin A. Two other antibiotics 70-B and 70-C have never been described and therefore are new antibiotics. The physical-chemical and biological characteristics of these preparations were described and further researched. Determination of the optimal growth conditions to cultivate actinomycete-producer strain IMV-70 and development of methods to isolate, purify, and accumulate preparations of the new antibiotic no. 70 enable us to research further the potential of this new class of antibiotics.

Highlights

In the recent decades, pathogenic microorganisms with resistance to common drugs have become increasingly widespread; some examples include methicillin-resistant [1,2,3,4] strains of Staphylococcus aureus (MRSA), vancomycin-resistant strains of S. aureus (MRCNS or “methicillin-resistant coagulase-negative staphylococci”), drug-resistant strains of Streptococcus pneumoniae (DRSP), and vancomycin-intermediate strains of S. aureus (VISA) [1,2,3,4]
This paper describes the research of the producer strain IMV-70 and the highly active antibiotic compound no. 70 which it produces
Strains of Staphylococcus haemolyticus NMR 1626, NMR 1742, Staphylococcus epidermidis NMR 351, NMR 793, Streptococcus agalactiae NMR 303, NMR 685, and NMR 1002, and Enterococcus faecalis NMR 425, NMR 118, NMR 670, and NMR 733 were isolated from urine; S. haemolyticus NMR 1642 and NMR 1656 from prostatic fluid; S. agalactiae NMR 782 and Streptococcus oralis NMR 1565 from respiratory tract specimen; S. epidermidis NMR 813 from vaginal smear; S. epidermidis NMR 1694 and Enterococcus hirae NMR 459 from wound matter; S. haemolyticus NMR 781 and Staphylococcus lugdunensis NMR 348 from nasal smear; S. haemolyticus NMR 713 from eye mucus; Streptococcus pneumoniae NMR 1150 from throat smear of infected patients

Summary

Introduction

Pathogenic microorganisms with resistance to common drugs have become increasingly widespread; some examples include methicillin-resistant [1,2,3,4] strains of Staphylococcus aureus (MRSA), vancomycin-resistant strains of S. aureus (MRCNS or “methicillin-resistant coagulase-negative staphylococci”), drug-resistant strains of Streptococcus pneumoniae (DRSP), and vancomycin-intermediate strains of S. aureus (VISA) [1,2,3,4]. MRSA have been viewed as one of the leading nosocomial pathogens [5,6,7]. At the same time the rate of MRCNS occurrence rose to 70–80% without substantial variation by region. These developments lead to significant complications in treating infections and pose a serious challenge to modern medicine. The search for new natural antibiotics that overcome drug resistance of pathogenic microflora is a viable solution to this problem. Such research necessitates the systematic screening of producers of antibacterial antibiotics

Objectives

Methods

Results